Kim Janda insider trades: Sorrento Therapeutics (SRNE) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Kim reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 27, 2021 | SRNE | ↓ Sell | 3,000 | $5.88 | $18K | Direct | Dec 27, 2021 (0d) |
| Sep 27, 2021 | SRNE | ↓ Sell | 42,357 | $8.02 | $340K | Direct | Sep 28, 2021 (1d) |
| Sep 13, 2021 | SRNE | ↓ Sell | 8,000 | $8.04 | $64K | Direct | Sep 14, 2021 (1d) |
| Apr 12, 2021 | SRNE | ↓ Sell | 1,900 | $6.97 | $13K | Direct | Apr 15, 2021 (3d) |
| Feb 3, 2017 | SRNE | ↑ Buy | 3,000 | $5.15 | $15K | Direct | Feb 3, 2017 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Kim Janda's insider trades
Kim Janda is a director at Sorrento Therapeutics (SRNE). Since Feb 3, 2017, Kim has reported 1 open-market purchase worth $15K and 4 sales worth $435K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (16 filings), option exercises (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every SRNE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.